drugset / Trial / NCT00741013

Quantifying Airway Inflammation With Radiologic Tests

NCT00741013

RandomizedParallel-groupQuadruple-blindTreatment

Summary

In this randomized, double-blind, placebo controlled trial we used positron emission tomography to determine if lovastatin or recombinant human activated protein C exhibit anti-inflammatory effects in humans following intrabronchial installation of lipopolysaccharide (LPS or endotoxin).

Timeline

Start
2007-03
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Lovastatin Small molecule 80 mg Oral
Subject recombinant human activated protein C Protein / enzyme biologic 24 ug/kg Intravenous

Indications